AstraZeneca PLC Announces Progress On Global PARTHENON Clinical Trial Program With BRILINTA (Ticagrelor) In High-Risk Cardiovascular Disease Patient Populations In Advance Of American College of Cardiology Scientific Session

Published: Mar 17, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) today announced it has completed patient enrollment approximately four months ahead of plan in the Phase III clinical trial EUCLID studying BRILINTA® (ticagrelor) tablets. Part of PARTHENON, AstraZeneca’s largest clinical trial program, EUCLID has randomized more than 13,500 patients globally with peripheral artery disease (PAD); approximately 20 percent are patients in the United States (US) from more than 300 active clinical trial sites across the country. EUCLID is designed to evaluate the effects of ticagrelor (monotherapy) compared to clopidogrel (monotherapy) on cardiovascular (CV) events and safety in PAD patients. Ticagrelor is currently not approved for the treatment of patients with PAD.

Help employers find you! Check out all the jobs and post your resume.

Back to news